SHILPAMED Shilpa Medicare Ltd Product Launches Announcement 2024 - FDA Approval Shilpa Medicare Ltd has received USFDA approval for its Bortezomib Injection, a new formulation for treating multiple myeloma and mantle cell lymphoma, marking a significant addition to its injectable portfolio. The US market for the existing Bortezomib product is approximately USD 95 million as of Q4 2023..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd